Reported Earlier, Lexicon Awaits FDA Decision After Advisory Committee Raises Concerns On Zynquista For Type 1 Diabetes With Kidney Complications
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals is awaiting an FDA decision on Zynquista for Type 1 Diabetes with kidney complications after an Advisory Committee raised concerns. The committee voted 11 to 3 against the benefits outweighing the risks for certain patients, though some members supported its use in alternative sub-populations.
November 01, 2024 | 8:17 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lexicon Pharmaceuticals faces uncertainty as the FDA reviews Zynquista for T1D with kidney complications. An Advisory Committee voted against its benefits outweighing risks for certain patients, but some support exists for alternative sub-populations.
The Advisory Committee's vote against the benefits of Zynquista for certain patients suggests potential challenges in gaining FDA approval, which could negatively impact Lexicon's stock in the short term. However, some support for alternative sub-populations may mitigate the impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100